Dr Andrea Mohr

Mohr, A., Chu, T., Brooke, GN. and Zwacka, RM., (2019). MSC.sTRAIL Has Better Efficacy than MSC.FL-TRAIL and in Combination with AKTi Blocks Pro-Metastatic Cytokine Production in Prostate Cancer Cells. Cancers. 11 (4), 568-568

Mohr, A., Deedigan, L., Jencz, S., Mehrabadi, Y., Houlden, L., Albarenque, S-M. and Zwacka, RM., (2018). Caspase-10: a molecular switch from cell-autonomous apoptosis to communal cell death in response to chemotherapeutic drug treatment.. Cell Death and Differentiation. 25 (2), 340-352

Mohr, A. and Zwacka, RM., (2018). The future of mesenchymal stem cell-based therapeutic approaches for cancer – From cells to ghosts. Cancer Letters. 414, 239-249

Mohr, A., Yu, R. and Zwacka, RM., (2015). TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill. BMC Cancer. 15 (1), 494-

Arora, J., Zwacka, RM. and Mohr, A., (2015). Development of a FACS-based Smac/DIABLO release assay to monitor individual drug responses and to pave the way towards patient-tailored therapies. Journal of Inflammation. 12 (S1)

Yu, R., Albarenque, SM., Cool, RH., Quax, WJ., Mohr, A. and Zwacka, RM., (2014). DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer. Cancer Biology & Therapy. 15 (12), 1658-1666

Yu, R., Deedigan, L., Albarenque, SM., Mohr, A. and Zwacka, RM., (2013). Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects. Cell Death & Disease. 4 (2), e503-e503

Yu, R., Deedigan, L., Albarenque, SM., Mohr, A. and Zwacka, RM., (2013). Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.. Cell death & disease. 4, creators-Mohr=3AAndrea=3A=3A

Büneker, CK., Yu, R., Deedigan, L., Mohr, A. and Zwacka, RM., (2012). IFN-γ combined with targeting of XIAP leads to increased apoptosis-sensitisation of TRAIL resistant pancreatic carcinoma cells. Cancer Letters. 316 (2), 168-177

B�neker, CK., Yu, R., Deedigan, L., Mohr, A. and Zwacka, RM., (2012). IFN-? combined with targeting of XIAP leads to increased apoptosis-sensitisation of TRAIL resistant pancreatic carcinoma cells.. Cancer letters. 316 (2), 168-77

Albarenque, SM., Zwacka, RM. and Mohr, A., (2011). Both human and mouse mesenchymal stem cells promote breast cancer metastasis. Stem Cell Research. 7 (2), 163-171

Stadel, D., Mohr, A., Ref, C., MacFarlane, M., Zhou, S., Humphreys, R., Bachem, M., Cohen, G., Möller, P., Zwacka, RM., Debatin, K-M. and Fulda, S., (2010). TRAIL-Induced Apoptosis Is Preferentially Mediated via TRAIL Receptor 1 in Pancreatic Carcinoma Cells and Profoundly Enhanced by XIAP Inhibitors. Clinical Cancer Research. 16 (23), 5734-5749

Mohr, A., Albarenque, SM., Deedigan, L., Yu, R., Reidy, M., Fulda, S. and Zwacka, RM., (2010). Targeting of XIAP Combined with Systemic Mesenchymal Stem Cell-Mediated Delivery of sTRAIL Ligand Inhibits Metastatic Growth of Pancreatic Carcinoma Cells. Stem Cells. 28 (11), 2109-2120

Zwacka, (2009). The TRAIL-receptor-1: TRAIL-receptor-3 and -4 ratio is a predictor for TRAIL sensitivity of cancer cells. Oncology Reports. 21 (5), 1289-1295

Häcker, S., Dittrich, A., Mohr, A., Schweitzer, T., Rutkowski, S., Krauss, J., Debatin, K-M. and Fulda, S., (2009). Histone deacetylase inhibitors cooperate with IFN-γ to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene. 28 (35), 3097-3110

Mohr, A., Büneker, C., Gough, RP. and Zwacka, RM., (2008). MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release. Oncogene. 27 (6), 763-774

Murray, TVA., McMahon, JM., Howley, BA., Stanley, A., Ritter, T., Mohr, A., Zwacka, R. and Fearnhead, HO., (2008). A non-apoptotic role for caspase-9 in muscle differentiation. Journal of Cell Science. 121 (22), 3786-3793

Mohr, A., Lyons, M., Deedigan, L., Harte, T., Shaw, G., Howard, L., Barry, F., O'Brien, T. and Zwacka, R., (2008). Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. Journal of Cellular and Molecular Medicine. 12 (6b), 2628-2643

Murray, TVA., McMahon, JM., Howley, BA., Stanley, A., Ritter, T., Mohr, A., Zwacka, RM. and Fearnhead, HO., (2008). A non-apoptotic role for caspase-9 in muscle differentiation.. Journal of Cell Science. 121 (Pt 22), 3786-93

Mohr, A. and Zwacka, RM., (2007). In situ trapping of initiator caspases reveals intermediate surprises. Cell Biology International. 31 (5), 526-530

Mohr, A., Lyons, M., Mohr, W. and Zwacka, R., (2007). Gentherapeutische Strategien gegen das kolorektale Karzinom. DMW - Deutsche Medizinische Wochenschrift. 132 (11), 567-570

Mohr, A., Lyons, M., Mohr, W. and Zwacka, R., (2007). Gentherapeutische Strategien gegen das kolorektale Karzinom. TumorDiagnostik & Therapie. 28 (3), 129-132

Mohr, A., Lyons, M., Mohr, W. and Zwacka, RM., (2007). Gentherapeutische Strategien gegen das kolorektale Karzinom [Gene therapy strategies for colorectal cancer]. Deutsche medizinische Wochenschrift (1946). 132 (11), 567-570

Braeuer, SJ., Büneker, C., Mohr, A. and Zwacka, RM., (2006). Constitutively Activated Nuclear Factor-κB, but not Induced NF-κB, Leads to TRAIL Resistance by Up-Regulation of X-Linked Inhibitor of Apoptosis Protein in Human Cancer Cells. Molecular Cancer Research. 4 (10), 715-728

Behrend, L., Mohr, A., Dick, T. and Zwacka, RM., (2005). Manganese Superoxide Dismutase Induces p53-Dependent Senescence in Colorectal Cancer Cells. Molecular and Cellular Biology. 25 (17), 7758-7769

Mohr, A., Zwacka, RM., Jarmy, G., Büneker, C., Schrezenmeier, H., Döhner, K., Beltinger, C., Wiesneth, M., Debatin, K-M. and Stahnke, K., (2005). Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis. Oncogene. 24 (14), 2421-2429

Mohr, A., Zwacka, RM., Debatin, K-M. and Stahnke, K., (2004). A novel method for the combined flow cytometric analysis of cell cycle and cytochrome c release. Cell Death & Differentiation. 11 (10), 1153-1154

Mohr, A., Henderson, G., Dudus, L., Herr, I., Kuerschner, T., Debatin, K-M., Weiher, H., Fisher, KJ. and Zwacka, RM., (2004). AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression. Gene Therapy. 11 (6), 534-543

Stahnke, K., Mohr, A., Liu, J., Meyer, LH., Karawajew, L. and Debatin, K-M., (2004). Identification of deficient mitochondrial signaling in apoptosis resistant leukemia cells by flow cytometric analysis of intracellular cytochrome c, caspase-3 and apoptosis. Apoptosis. 9 (4), 457-465

Stahnke, K., Eckhoff, S., Mohr, A., Meyer, LH. and Debatin, K-M., (2003). Apoptosis induction in peripheral leukemia cells by remission induction treatment in vivo: selective depletion and apoptosis in a CD34+ subpopulation of leukemia cells. Leukemia. 17 (11), 2130-2139

Stefan, M., Koch, A., Mancini, A., Mohr, A., Weidner, KM., Niemann, H. and Tamura, T., (2001). Src Homology 2-containing Inositol 5-Phosphatase 1 Binds to the Multifunctional Docking Site of c-Met and Potentiates Hepatocyte Growth Factor-induced Branching Tubulogenesis. Journal of Biological Chemistry. 276 (5), 3017-3023

Mohr, A., Zwacka, RM., Schrezenmeier, H., Döhner, K., Wiesneth, M., Stahnke, K. and Debatin, KM., (2003). Caspase-8L expression contributes to the protection of CD34+hematopoietic progenitor cells from C95-mediated apoptosis.

Mohr, A., Henderson, G., Dudus, L., Herr, I., Debatin, KM., Weiher, H., Fisher, K. and Zwacka, RM., (2003). AAV encoded expression of TRAIL in experimental human colorectal tumor cells leads to tumor regression.